“Back to the Future”: Developments in Immunotherapy with David Gandara, MD

ByShikha Jain, MD, FACP

ByDavid R. Gandara, MD

In this episode, host Shikha Jain, MD, speaks with David Gandara, MD, about how ctDNA and CAR-T cell therapies are transforming precision medicine, the importance of patient reported outcomes and more.

Welcome to another exciting episode of Oncology Overdrive 0:14
About Gandara 0:19
The interview 1:02
Can you tell me a little more about what you are working on now? 1:25
How did you get engaged with the community in Hawaii? 6:30
What do you think is going to happen with ctDNA moving forward? 8:29
Can you utilize ctDNA and minimal residual disease information to determine how long patients need to be on adjuvant therapy?11:42
How did you get into the ctDNA space?15:06
How do you see AI transforming health care beyond providing patients with more information and taking more ownership of their health?18:28
Can you tell us more about how a second opinion clinic works? How did this type of clinic develop and become part of what you do?23:17
What are some of your predictions as to what will happen in oncology care over the next ten to twenty years?29:00
If someone could only listen to the last few minutes of this episode, what would you want listeners to take away? 37:30
How to contact Gandara 38:47
Thanks for listening 39:10

David Gandara, MD, is a clinician-scientist and lung cancer specialist internationally recognized for his expertise in thoracic cancers, cancer drug development and biomarker development.

We’d love to hear from you! Send your comments/questions to Dr. Jain at oncologyoverdrive@healio.com. Follow Healio on X and LinkedIn: @HemOncToday and https://www.linkedin.com/company/hemonctoday/. Follow Dr. Jain on X: @ShikhaJainMD. Dr. Gandara can be reached via email drgandara@ucdavis.edu.

Published by:

Sources/Disclosures

Collapse

Disclosures: Jain reports no relevant financial disclosures. Gandara reports institutional research grants from Astex, Amgen and Genentech; institutional consulting for AstraZenica, Exact Sciences, Genentech, Guardant Health, IO Biotech and Oncohost; consulting for Adagene, Henlius USA, Foundation Medicine and Sanofi; serves on the advisory board of Abbvie, Janssen, Merck, Mirati, Regeneron and Revolution Medicine.

Read more

“Back to the Future”: Developments in Immunotherapy with David Gandara, MD

Oncology Overdrive

Related Content